Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
Sara Nik

Sara Nik Analyst Performance

Vice President, Equity Research at HC Wainwright

Sara Nik is a stock analyst at HC Wainwright in the medical sector, covering 4 publicly traded companies. Over the past year, Sara Nik has issued 13 stock ratings, including buy and hold recommendations. While full access to Sara Nik's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sara Nik's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
92.31% 12 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.3%12 ratings
Hold7.7%1 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Sara Nik at HC Wainwright, the majority (92.3%) have been Buy recommendations, followed by 7.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
4 companies

Sara Nik, an analyst at HC Wainwright, currently covers 4 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

Sara Nik of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
100.0%

Sara Nik's Ratings History at HC Wainwright

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
4/20/2026Reiterated Rating$0.73$3.00Buy
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3/24/2026Reiterated Rating$2.12$22.00Buy
Curis, Inc. stock logo
CRIS
Curis
3/20/2026Reiterated Rating$0.76$17.00Buy
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
12/11/2025Reiterated Rating$4.83$22.00Buy
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
12/8/2025Initiated Coverage$1.13$3.00Buy
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
12/8/2025Initiated Coverage$1.13$3.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
11/14/2025Downgrade$217.77Neutral
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
10/21/2025Reiterated Rating$102.39$150.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
10/9/2025Boost Price Target$107.84$150.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9/26/2025Boost Price Target$84.76$110.00Buy
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
9/10/2025Reiterated Rating$10.18$100.00Buy
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
8/27/2025Reiterated Rating$13.83$100.00Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
8/8/2025Reiterated Rating$61.73$74.00Buy